VivoSeq
Other

Hypoplastic Left Heart Syndrome

7

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Hypoplastic Left Heart Syndrome is an early-stage landscape with 7 programs across 3 companies. The most active players are Mononuclear Therapeutics Ltd., Gilead, Alnylam Pharmaceuticals. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Mononuclear Therapeutics Ltd.

1 program

Phase 1Gilead logo

Gilead

1 program

ApprovedAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSCell therapy117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

8

clinical trials

Terminated2 · 25%
Completed2 · 25%
Active, not recruiting2 · 25%
Not yet recruiting1 · 13%
Unknown status1 · 13%

Clinical Trials

Trial Activity

8 trials

Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome
Active, not recruiting·TTimothy J Nelson, MD, PhD·Phase 2·NCT03779711·95 enrolled
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Active, not recruiting·LLongeveron Inc.·Phase 2·NCT04925024·40 enrolled
Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)
Not yet recruiting·EEmory University·Phase 1·NCT06461676·12 enrolled
Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome
Completed·TTimothy J Nelson, MD, PhD·Phase 1·NCT01883076·30 enrolled
The CHILD Trial: Hypoplastic Left Heart Syndrome Study.
Completed·—·Phase 1·NCT03406884·25 enrolled
Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome
Terminated·LLongeveron Inc.·Phase 1·NCT02398604·5 enrolled
Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome
Terminated·—·Phase 1·NCT01445041·7 enrolled
Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)
Unknown status·LLongeveron Inc.·Phase 1/2·NCT03525418·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)